Biotech

A new wave of regulatory caution from Beijing is redefining the pathway for Chinese tech and biotech firms seeking offshore listings, with significant implications for…

A profitable Hong Kong-based biotechnology company is moving toward a public listing to finance the development of treatments for Alzheimer’s and other neurological diseases, a…

The Missing Black Holes: A Gravitational-Wave Clue to Stellar Annihilation For six decades, astrophysicists have theorized the existence of a stellar cataclysm so violent it…

For global biotech professionals and investors, the contrast between Hong Kong and Singapore offers a cautionary tale—and a reminder that institutional infrastructure, talent pipelines, and…

For global pharmaceutical professionals, the prospect of a Chinese company successfully navigating US biological drug approval for the first time signals a shift in competitive…

Take Away China’s biotech sector is no longer content with manufacturing generics; it is now a primary arena for strategic national investment, aiming to redefine…

For global biotech investors and pharmaceutical strategists, the lesson is clear: China’s life sciences future is increasingly a story of regional ecosystems, not just national…

A Chinese diagnostic firm’s plan to expand in Hong Kong signals how pandemic-era public health partnerships can become a launchpad for long-term commercial strategy in…

The move signals a strategic pivot from unfettered capital access to controlled growth, prioritizing regulatory oversight and national interest in sensitive sectors. Chinese regulators are…

Three decades of parallel biotech ambition have left Hong Kong trailing Singapore by a significant distance. Yet the emergence of the Greater Bay Area offers…